nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ABCB1—Mitomycin—urinary bladder cancer	0.0935	0.271	CbGbCtD
Tacrolimus—ALB—Fluorouracil—urinary bladder cancer	0.044	0.128	CbGbCtD
Tacrolimus—CYP3A4—Thiotepa—urinary bladder cancer	0.0425	0.123	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—urinary bladder cancer	0.0295	0.0857	CbGbCtD
Tacrolimus—ABCB1—Gemcitabine—urinary bladder cancer	0.0269	0.0781	CbGbCtD
Tacrolimus—ALB—Methotrexate—urinary bladder cancer	0.0243	0.0704	CbGbCtD
Tacrolimus—ABCB1—Cisplatin—urinary bladder cancer	0.0196	0.0567	CbGbCtD
Tacrolimus—ABCB1—Etoposide—urinary bladder cancer	0.0192	0.0557	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—urinary bladder cancer	0.0131	0.038	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—urinary bladder cancer	0.0127	0.0368	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—urinary bladder cancer	0.0115	0.0334	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—urinary bladder cancer	0.00785	0.0228	CbGbCtD
Tacrolimus—ABCA5—prostate gland—urinary bladder cancer	0.00781	0.0662	CbGeAlD
Tacrolimus—ABCA5—seminal vesicle—urinary bladder cancer	0.00661	0.056	CbGeAlD
Tacrolimus—PPP3CA—prostate gland—urinary bladder cancer	0.00528	0.0447	CbGeAlD
Tacrolimus—ABCA5—urethra—urinary bladder cancer	0.00523	0.0443	CbGeAlD
Tacrolimus—PPP3CA—seminal vesicle—urinary bladder cancer	0.00446	0.0378	CbGeAlD
Tacrolimus—ABCA5—female reproductive system—urinary bladder cancer	0.00427	0.0362	CbGeAlD
Tacrolimus—MTOR—prostate gland—urinary bladder cancer	0.0039	0.0331	CbGeAlD
Tacrolimus—ABCA5—vagina—urinary bladder cancer	0.00386	0.0327	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—urinary bladder cancer	0.00374	0.0317	CbGeAlD
Tacrolimus—PPP3CA—renal system—urinary bladder cancer	0.0036	0.0305	CbGeAlD
Tacrolimus—PPP3CA—urethra—urinary bladder cancer	0.00353	0.03	CbGeAlD
Tacrolimus—FKBP1A—prostate gland—urinary bladder cancer	0.00351	0.0297	CbGeAlD
Tacrolimus—MTOR—seminal vesicle—urinary bladder cancer	0.0033	0.028	CbGeAlD
Tacrolimus—CYP3A4—urine—urinary bladder cancer	0.00319	0.0271	CbGeAlD
Tacrolimus—FKBP1A—seminal vesicle—urinary bladder cancer	0.00297	0.0251	CbGeAlD
Tacrolimus—PPP3CA—female reproductive system—urinary bladder cancer	0.00288	0.0244	CbGeAlD
Tacrolimus—MTOR—epithelium—urinary bladder cancer	0.00287	0.0243	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—urinary bladder cancer	0.00276	0.0234	CbGeAlD
Tacrolimus—ORM1—prostate gland—urinary bladder cancer	0.00275	0.0233	CbGeAlD
Tacrolimus—MTOR—renal system—urinary bladder cancer	0.00266	0.0225	CbGeAlD
Tacrolimus—PPP3CA—vagina—urinary bladder cancer	0.00261	0.0221	CbGeAlD
Tacrolimus—FKBP1A—epithelium—urinary bladder cancer	0.00258	0.0218	CbGeAlD
Tacrolimus—ABCA5—lymph node—urinary bladder cancer	0.0025	0.0212	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—urinary bladder cancer	0.00248	0.021	CbGeAlD
Tacrolimus—FKBP1A—renal system—urinary bladder cancer	0.00239	0.0203	CbGeAlD
Tacrolimus—FKBP1A—urethra—urinary bladder cancer	0.00235	0.0199	CbGeAlD
Tacrolimus—MTOR—female reproductive system—urinary bladder cancer	0.00213	0.018	CbGeAlD
Tacrolimus—MTOR—vagina—urinary bladder cancer	0.00192	0.0163	CbGeAlD
Tacrolimus—FKBP1A—female reproductive system—urinary bladder cancer	0.00191	0.0162	CbGeAlD
Tacrolimus—FKBP1A—vagina—urinary bladder cancer	0.00173	0.0147	CbGeAlD
Tacrolimus—PPP3CA—lymph node—urinary bladder cancer	0.00169	0.0143	CbGeAlD
Tacrolimus—CYP3A5—prostate gland—urinary bladder cancer	0.00153	0.0129	CbGeAlD
Tacrolimus—ORM1—female reproductive system—urinary bladder cancer	0.0015	0.0127	CbGeAlD
Tacrolimus—MTOR—lymph node—urinary bladder cancer	0.00125	0.0106	CbGeAlD
Tacrolimus—FKBP1A—lymph node—urinary bladder cancer	0.00112	0.00949	CbGeAlD
Tacrolimus—CYP3A5—renal system—urinary bladder cancer	0.00104	0.00882	CbGeAlD
Tacrolimus—ORM1—lymph node—urinary bladder cancer	0.000877	0.00743	CbGeAlD
Tacrolimus—ABCB1—prostate gland—urinary bladder cancer	0.000811	0.00688	CbGeAlD
Tacrolimus—CYP3A4—renal system—urinary bladder cancer	0.000781	0.00662	CbGeAlD
Tacrolimus—ALB—lymph node—urinary bladder cancer	0.000769	0.00652	CbGeAlD
Tacrolimus—CYP3A5—vagina—urinary bladder cancer	0.000754	0.00639	CbGeAlD
Tacrolimus—ABCB1—seminal vesicle—urinary bladder cancer	0.000686	0.00582	CbGeAlD
Tacrolimus—CYP3A4—female reproductive system—urinary bladder cancer	0.000626	0.0053	CbGeAlD
Tacrolimus—ABCB1—epithelium—urinary bladder cancer	0.000596	0.00505	CbGeAlD
Tacrolimus—ABCB1—renal system—urinary bladder cancer	0.000553	0.00469	CbGeAlD
Tacrolimus—ABCB1—urethra—urinary bladder cancer	0.000543	0.0046	CbGeAlD
Tacrolimus—ABCB1—female reproductive system—urinary bladder cancer	0.000443	0.00375	CbGeAlD
Tacrolimus—ABCB1—vagina—urinary bladder cancer	0.0004	0.00339	CbGeAlD
Tacrolimus—ABCB1—lymph node—urinary bladder cancer	0.000259	0.0022	CbGeAlD
Tacrolimus—Visual impairment—Epirubicin—urinary bladder cancer	8.1e-05	0.000217	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.09e-05	0.000217	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.08e-05	0.000217	CcSEcCtD
Tacrolimus—Chills—Methotrexate—urinary bladder cancer	8.06e-05	0.000216	CcSEcCtD
Tacrolimus—Diarrhoea—Cisplatin—urinary bladder cancer	7.95e-05	0.000214	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—urinary bladder cancer	7.95e-05	0.000213	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—urinary bladder cancer	7.93e-05	0.000213	CcSEcCtD
Tacrolimus—Vomiting—Gemcitabine—urinary bladder cancer	7.93e-05	0.000213	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—urinary bladder cancer	7.92e-05	0.000213	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—urinary bladder cancer	7.87e-05	0.000211	CcSEcCtD
Tacrolimus—Rash—Gemcitabine—urinary bladder cancer	7.86e-05	0.000211	CcSEcCtD
Tacrolimus—Dermatitis—Gemcitabine—urinary bladder cancer	7.86e-05	0.000211	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—urinary bladder cancer	7.85e-05	0.000211	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—urinary bladder cancer	7.85e-05	0.000211	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—urinary bladder cancer	7.83e-05	0.00021	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—urinary bladder cancer	7.82e-05	0.00021	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—urinary bladder cancer	7.82e-05	0.00021	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—urinary bladder cancer	7.81e-05	0.00021	CcSEcCtD
Tacrolimus—Headache—Gemcitabine—urinary bladder cancer	7.81e-05	0.00021	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—urinary bladder cancer	7.8e-05	0.000209	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—urinary bladder cancer	7.8e-05	0.000209	CcSEcCtD
Tacrolimus—Vomiting—Fluorouracil—urinary bladder cancer	7.8e-05	0.000209	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—urinary bladder cancer	7.79e-05	0.000209	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—urinary bladder cancer	7.78e-05	0.000209	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—urinary bladder cancer	7.78e-05	0.000209	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—urinary bladder cancer	7.74e-05	0.000208	CcSEcCtD
Tacrolimus—Rash—Fluorouracil—urinary bladder cancer	7.73e-05	0.000208	CcSEcCtD
Tacrolimus—Dermatitis—Fluorouracil—urinary bladder cancer	7.73e-05	0.000207	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—urinary bladder cancer	7.72e-05	0.000207	CcSEcCtD
Tacrolimus—Headache—Fluorouracil—urinary bladder cancer	7.68e-05	0.000206	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.68e-05	0.000206	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.66e-05	0.000206	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—urinary bladder cancer	7.65e-05	0.000206	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—urinary bladder cancer	7.64e-05	0.000205	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.64e-05	0.000205	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—urinary bladder cancer	7.62e-05	0.000205	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—urinary bladder cancer	7.62e-05	0.000205	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—urinary bladder cancer	7.59e-05	0.000204	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.57e-05	0.000203	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—urinary bladder cancer	7.56e-05	0.000203	CcSEcCtD
Tacrolimus—Chills—Epirubicin—urinary bladder cancer	7.54e-05	0.000202	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—urinary bladder cancer	7.54e-05	0.000202	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—urinary bladder cancer	7.51e-05	0.000202	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—urinary bladder cancer	7.49e-05	0.000201	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—urinary bladder cancer	7.43e-05	0.000199	CcSEcCtD
Tacrolimus—Nausea—Gemcitabine—urinary bladder cancer	7.41e-05	0.000199	CcSEcCtD
Tacrolimus—Vomiting—Cisplatin—urinary bladder cancer	7.39e-05	0.000198	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—urinary bladder cancer	7.37e-05	0.000198	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—urinary bladder cancer	7.36e-05	0.000198	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—urinary bladder cancer	7.35e-05	0.000197	CcSEcCtD
Tacrolimus—Rash—Cisplatin—urinary bladder cancer	7.33e-05	0.000197	CcSEcCtD
Tacrolimus—Dermatitis—Cisplatin—urinary bladder cancer	7.32e-05	0.000197	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—urinary bladder cancer	7.32e-05	0.000196	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—urinary bladder cancer	7.32e-05	0.000196	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—urinary bladder cancer	7.29e-05	0.000196	CcSEcCtD
Tacrolimus—Nausea—Fluorouracil—urinary bladder cancer	7.28e-05	0.000196	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—urinary bladder cancer	7.27e-05	0.000195	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—urinary bladder cancer	7.25e-05	0.000195	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—urinary bladder cancer	7.25e-05	0.000195	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—urinary bladder cancer	7.22e-05	0.000194	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—urinary bladder cancer	7.22e-05	0.000194	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.22e-05	0.000194	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—urinary bladder cancer	7.21e-05	0.000194	CcSEcCtD
Tacrolimus—Tension—Epirubicin—urinary bladder cancer	7.18e-05	0.000193	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—urinary bladder cancer	7.16e-05	0.000192	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—urinary bladder cancer	7.1e-05	0.000191	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—urinary bladder cancer	7.08e-05	0.00019	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—urinary bladder cancer	7.05e-05	0.000189	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—urinary bladder cancer	7.05e-05	0.000189	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—urinary bladder cancer	7.04e-05	0.000189	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—urinary bladder cancer	7.03e-05	0.000189	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—urinary bladder cancer	7.02e-05	0.000189	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—urinary bladder cancer	7.02e-05	0.000189	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.01e-05	0.000188	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—urinary bladder cancer	7e-05	0.000188	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—urinary bladder cancer	6.98e-05	0.000187	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—urinary bladder cancer	6.95e-05	0.000186	CcSEcCtD
Tacrolimus—Nausea—Cisplatin—urinary bladder cancer	6.91e-05	0.000185	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—urinary bladder cancer	6.89e-05	0.000185	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—urinary bladder cancer	6.87e-05	0.000184	CcSEcCtD
Tacrolimus—Cough—Methotrexate—urinary bladder cancer	6.82e-05	0.000183	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—urinary bladder cancer	6.81e-05	0.000183	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.79e-05	0.000182	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—urinary bladder cancer	6.77e-05	0.000182	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—urinary bladder cancer	6.77e-05	0.000182	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—urinary bladder cancer	6.77e-05	0.000182	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—urinary bladder cancer	6.77e-05	0.000182	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—urinary bladder cancer	6.76e-05	0.000182	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—urinary bladder cancer	6.72e-05	0.00018	CcSEcCtD
Tacrolimus—Rash—Etoposide—urinary bladder cancer	6.72e-05	0.00018	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—urinary bladder cancer	6.71e-05	0.00018	CcSEcCtD
Tacrolimus—Headache—Etoposide—urinary bladder cancer	6.67e-05	0.000179	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—urinary bladder cancer	6.67e-05	0.000179	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—urinary bladder cancer	6.65e-05	0.000179	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—urinary bladder cancer	6.65e-05	0.000179	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—urinary bladder cancer	6.65e-05	0.000179	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—urinary bladder cancer	6.64e-05	0.000178	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—urinary bladder cancer	6.63e-05	0.000178	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.61e-05	0.000177	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—urinary bladder cancer	6.6e-05	0.000177	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—urinary bladder cancer	6.57e-05	0.000177	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—urinary bladder cancer	6.57e-05	0.000176	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—urinary bladder cancer	6.57e-05	0.000176	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—urinary bladder cancer	6.56e-05	0.000176	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—urinary bladder cancer	6.55e-05	0.000176	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—urinary bladder cancer	6.55e-05	0.000176	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—urinary bladder cancer	6.51e-05	0.000175	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—urinary bladder cancer	6.46e-05	0.000174	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—urinary bladder cancer	6.43e-05	0.000173	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—urinary bladder cancer	6.43e-05	0.000173	CcSEcCtD
Tacrolimus—Cough—Epirubicin—urinary bladder cancer	6.38e-05	0.000171	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.38e-05	0.000171	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—urinary bladder cancer	6.38e-05	0.000171	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—urinary bladder cancer	6.34e-05	0.00017	CcSEcCtD
Tacrolimus—Infection—Methotrexate—urinary bladder cancer	6.34e-05	0.00017	CcSEcCtD
Tacrolimus—Nausea—Etoposide—urinary bladder cancer	6.33e-05	0.00017	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—urinary bladder cancer	6.32e-05	0.00017	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.28e-05	0.000169	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—urinary bladder cancer	6.26e-05	0.000168	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—urinary bladder cancer	6.26e-05	0.000168	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.25e-05	0.000168	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—urinary bladder cancer	6.23e-05	0.000167	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—urinary bladder cancer	6.23e-05	0.000167	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—urinary bladder cancer	6.23e-05	0.000167	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—urinary bladder cancer	6.22e-05	0.000167	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—urinary bladder cancer	6.21e-05	0.000167	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—urinary bladder cancer	6.2e-05	0.000166	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.18e-05	0.000166	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.17e-05	0.000166	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—urinary bladder cancer	6.15e-05	0.000165	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—urinary bladder cancer	6.1e-05	0.000164	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—urinary bladder cancer	6.09e-05	0.000164	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—urinary bladder cancer	6.08e-05	0.000163	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—urinary bladder cancer	6.08e-05	0.000163	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—urinary bladder cancer	6.07e-05	0.000163	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—urinary bladder cancer	6.06e-05	0.000163	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—urinary bladder cancer	6.02e-05	0.000162	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—urinary bladder cancer	5.98e-05	0.000161	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.97e-05	0.00016	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—urinary bladder cancer	5.97e-05	0.00016	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—urinary bladder cancer	5.96e-05	0.00016	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.95e-05	0.00016	CcSEcCtD
Tacrolimus—Infection—Epirubicin—urinary bladder cancer	5.93e-05	0.000159	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—urinary bladder cancer	5.91e-05	0.000159	CcSEcCtD
Tacrolimus—Shock—Epirubicin—urinary bladder cancer	5.87e-05	0.000158	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—urinary bladder cancer	5.86e-05	0.000157	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—urinary bladder cancer	5.85e-05	0.000157	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.85e-05	0.000157	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—urinary bladder cancer	5.84e-05	0.000157	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—urinary bladder cancer	5.83e-05	0.000156	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.81e-05	0.000156	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—urinary bladder cancer	5.8e-05	0.000156	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.77e-05	0.000155	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—urinary bladder cancer	5.77e-05	0.000155	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—urinary bladder cancer	5.76e-05	0.000155	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—urinary bladder cancer	5.76e-05	0.000155	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—urinary bladder cancer	5.76e-05	0.000155	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—urinary bladder cancer	5.74e-05	0.000154	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—urinary bladder cancer	5.73e-05	0.000154	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.72e-05	0.000154	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—urinary bladder cancer	5.69e-05	0.000153	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—urinary bladder cancer	5.69e-05	0.000153	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—urinary bladder cancer	5.69e-05	0.000153	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—urinary bladder cancer	5.67e-05	0.000152	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—urinary bladder cancer	5.64e-05	0.000151	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—urinary bladder cancer	5.62e-05	0.000151	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—urinary bladder cancer	5.58e-05	0.00015	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—urinary bladder cancer	5.57e-05	0.00015	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—urinary bladder cancer	5.55e-05	0.000149	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.52e-05	0.000148	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—urinary bladder cancer	5.52e-05	0.000148	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.51e-05	0.000148	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—urinary bladder cancer	5.5e-05	0.000148	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—urinary bladder cancer	5.49e-05	0.000147	CcSEcCtD
Tacrolimus—Pain—Methotrexate—urinary bladder cancer	5.46e-05	0.000146	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.44e-05	0.000146	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—urinary bladder cancer	5.43e-05	0.000146	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.42e-05	0.000145	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.41e-05	0.000145	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—urinary bladder cancer	5.4e-05	0.000145	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—urinary bladder cancer	5.39e-05	0.000145	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—urinary bladder cancer	5.37e-05	0.000144	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—urinary bladder cancer	5.36e-05	0.000144	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.34e-05	0.000143	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—urinary bladder cancer	5.32e-05	0.000143	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—urinary bladder cancer	5.31e-05	0.000142	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—urinary bladder cancer	5.27e-05	0.000141	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—urinary bladder cancer	5.26e-05	0.000141	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—urinary bladder cancer	5.26e-05	0.000141	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.22e-05	0.00014	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—urinary bladder cancer	5.19e-05	0.000139	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—urinary bladder cancer	5.16e-05	0.000139	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.15e-05	0.000138	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—urinary bladder cancer	5.15e-05	0.000138	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—urinary bladder cancer	5.11e-05	0.000137	CcSEcCtD
Tacrolimus—Pain—Epirubicin—urinary bladder cancer	5.11e-05	0.000137	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—urinary bladder cancer	5.07e-05	0.000136	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—urinary bladder cancer	5.04e-05	0.000135	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—urinary bladder cancer	5.04e-05	0.000135	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.03e-05	0.000135	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—urinary bladder cancer	5e-05	0.000134	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—urinary bladder cancer	4.96e-05	0.000133	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—urinary bladder cancer	4.92e-05	0.000132	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—urinary bladder cancer	4.92e-05	0.000132	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—urinary bladder cancer	4.91e-05	0.000132	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.88e-05	0.000131	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—urinary bladder cancer	4.86e-05	0.000131	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—urinary bladder cancer	4.8e-05	0.000129	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.77e-05	0.000128	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—urinary bladder cancer	4.76e-05	0.000128	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—urinary bladder cancer	4.74e-05	0.000127	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—urinary bladder cancer	4.72e-05	0.000127	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—urinary bladder cancer	4.72e-05	0.000127	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—urinary bladder cancer	4.72e-05	0.000127	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—urinary bladder cancer	4.72e-05	0.000127	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—urinary bladder cancer	4.7e-05	0.000126	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—urinary bladder cancer	4.58e-05	0.000123	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.55e-05	0.000122	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.52e-05	0.000121	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—urinary bladder cancer	4.51e-05	0.000121	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—urinary bladder cancer	4.4e-05	0.000118	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—urinary bladder cancer	4.39e-05	0.000118	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—urinary bladder cancer	4.37e-05	0.000117	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—urinary bladder cancer	4.37e-05	0.000117	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—urinary bladder cancer	4.36e-05	0.000117	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—urinary bladder cancer	4.28e-05	0.000115	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—urinary bladder cancer	4.22e-05	0.000113	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—urinary bladder cancer	4.22e-05	0.000113	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—urinary bladder cancer	4.08e-05	0.00011	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.07e-05	0.000109	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—urinary bladder cancer	4.06e-05	0.000109	CcSEcCtD
Tacrolimus—Rash—Methotrexate—urinary bladder cancer	4.02e-05	0.000108	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—urinary bladder cancer	4.02e-05	0.000108	CcSEcCtD
Tacrolimus—Headache—Methotrexate—urinary bladder cancer	4e-05	0.000107	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—urinary bladder cancer	3.96e-05	0.000106	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—urinary bladder cancer	3.95e-05	0.000106	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—urinary bladder cancer	3.91e-05	0.000105	CcSEcCtD
Tacrolimus—Vomiting—Epirubicin—urinary bladder cancer	3.8e-05	0.000102	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—urinary bladder cancer	3.79e-05	0.000102	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—urinary bladder cancer	3.78e-05	0.000101	CcSEcCtD
Tacrolimus—Rash—Epirubicin—urinary bladder cancer	3.76e-05	0.000101	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—urinary bladder cancer	3.76e-05	0.000101	CcSEcCtD
Tacrolimus—Headache—Epirubicin—urinary bladder cancer	3.74e-05	0.0001	CcSEcCtD
Tacrolimus—Dizziness—Doxorubicin—urinary bladder cancer	3.65e-05	9.81e-05	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—urinary bladder cancer	3.55e-05	9.52e-05	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—urinary bladder cancer	3.51e-05	9.43e-05	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—urinary bladder cancer	3.48e-05	9.35e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—urinary bladder cancer	3.48e-05	9.34e-05	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—urinary bladder cancer	3.46e-05	9.29e-05	CcSEcCtD
Tacrolimus—PPP3CA—Disease—SRC—urinary bladder cancer	3.38e-05	0.000205	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	3.36e-05	0.000204	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.35e-05	0.000203	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERBB2—urinary bladder cancer	3.33e-05	0.000202	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.33e-05	0.000202	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—urinary bladder cancer	3.32e-05	0.000202	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERBB2—urinary bladder cancer	3.32e-05	0.000201	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—urinary bladder cancer	3.28e-05	8.81e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—TSC1—urinary bladder cancer	3.27e-05	0.000198	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.27e-05	0.000198	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FGFR3—urinary bladder cancer	3.26e-05	0.000198	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—urinary bladder cancer	3.24e-05	0.000197	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RHOA—urinary bladder cancer	3.24e-05	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NCOR1—urinary bladder cancer	3.24e-05	0.000196	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—urinary bladder cancer	3.21e-05	0.000195	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.2e-05	0.000194	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ESR1—urinary bladder cancer	3.17e-05	0.000192	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.13e-05	0.00019	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JAG1—urinary bladder cancer	3.11e-05	0.000189	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.09e-05	0.000188	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.09e-05	0.000187	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERCC2—urinary bladder cancer	3.04e-05	0.000185	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—urinary bladder cancer	3.04e-05	0.000184	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MYC—urinary bladder cancer	3.03e-05	0.000184	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB2—urinary bladder cancer	3e-05	0.000182	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.99e-05	0.000181	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMP—urinary bladder cancer	2.98e-05	0.000181	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—urinary bladder cancer	2.97e-05	0.00018	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CDKN1A—urinary bladder cancer	2.97e-05	0.00018	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PTEN—urinary bladder cancer	2.96e-05	0.00018	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.94e-05	0.000178	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.91e-05	0.000176	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.86e-05	0.000174	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.86e-05	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MTHFR—urinary bladder cancer	2.86e-05	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TERT—urinary bladder cancer	2.85e-05	0.000173	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDKN1A—urinary bladder cancer	2.85e-05	0.000173	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL8—urinary bladder cancer	2.84e-05	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PTEN—urinary bladder cancer	2.84e-05	0.000172	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CDKN1A—urinary bladder cancer	2.84e-05	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FGFR3—urinary bladder cancer	2.84e-05	0.000172	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTEN—urinary bladder cancer	2.83e-05	0.000172	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—urinary bladder cancer	2.82e-05	0.000171	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EP300—urinary bladder cancer	2.82e-05	0.000171	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.8e-05	0.00017	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—urinary bladder cancer	2.8e-05	0.00017	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NQO1—urinary bladder cancer	2.79e-05	0.000169	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.77e-05	0.000168	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SRC—urinary bladder cancer	2.74e-05	0.000166	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PLAU—urinary bladder cancer	2.74e-05	0.000166	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IGF1—urinary bladder cancer	2.74e-05	0.000166	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—urinary bladder cancer	2.72e-05	0.000165	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.7e-05	0.000164	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EP300—urinary bladder cancer	2.7e-05	0.000164	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NAT2—urinary bladder cancer	2.7e-05	0.000164	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.66e-05	0.000161	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.66e-05	0.000161	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—urinary bladder cancer	2.65e-05	0.000161	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SRC—urinary bladder cancer	2.64e-05	0.00016	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SRC—urinary bladder cancer	2.62e-05	0.000159	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FGFR3—urinary bladder cancer	2.62e-05	0.000159	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.61e-05	0.000158	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—urinary bladder cancer	2.58e-05	0.000157	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—urinary bladder cancer	2.57e-05	0.000156	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.56e-05	0.000156	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CDKN1A—urinary bladder cancer	2.56e-05	0.000155	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—urinary bladder cancer	2.56e-05	0.000155	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—S100B—urinary bladder cancer	2.52e-05	0.000153	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RHOA—urinary bladder cancer	2.51e-05	0.000152	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.51e-05	0.000152	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.5e-05	0.000152	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.5e-05	0.000152	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EP300—urinary bladder cancer	2.44e-05	0.000148	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.43e-05	0.000147	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.43e-05	0.000147	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CREBBP—urinary bladder cancer	2.41e-05	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—urinary bladder cancer	2.41e-05	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDH1—urinary bladder cancer	2.4e-05	0.000145	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.39e-05	0.000145	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—urinary bladder cancer	2.38e-05	0.000144	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SRC—urinary bladder cancer	2.37e-05	0.000144	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.37e-05	0.000144	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.36e-05	0.000143	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—urinary bladder cancer	2.35e-05	0.000143	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	2.33e-05	0.000141	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—RRM2—urinary bladder cancer	2.33e-05	0.000141	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—urinary bladder cancer	2.32e-05	0.000141	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—urinary bladder cancer	2.31e-05	0.00014	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—urinary bladder cancer	2.3e-05	0.00014	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—urinary bladder cancer	2.27e-05	0.000138	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NCOR1—urinary bladder cancer	2.27e-05	0.000138	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.26e-05	0.000137	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IGF1—urinary bladder cancer	2.23e-05	0.000135	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CREBBP—urinary bladder cancer	2.23e-05	0.000135	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.2e-05	0.000134	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.19e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—urinary bladder cancer	2.18e-05	0.000132	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—urinary bladder cancer	2.17e-05	0.000132	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TYMS—urinary bladder cancer	2.16e-05	0.000131	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HPGDS—urinary bladder cancer	2.16e-05	0.000131	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO2—urinary bladder cancer	2.16e-05	0.000131	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.14e-05	0.00013	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	2.14e-05	0.00013	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	2.14e-05	0.00013	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—urinary bladder cancer	2.12e-05	0.000129	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—urinary bladder cancer	2.11e-05	0.000128	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.11e-05	0.000128	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTT1—urinary bladder cancer	2.09e-05	0.000127	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.07e-05	0.000125	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.06e-05	0.000125	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—urinary bladder cancer	2.05e-05	0.000125	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GPX1—urinary bladder cancer	2.05e-05	0.000124	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RHOA—urinary bladder cancer	2.05e-05	0.000124	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.04e-05	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—urinary bladder cancer	2.02e-05	0.000123	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.02e-05	0.000122	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RHOA—urinary bladder cancer	2.02e-05	0.000122	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.01e-05	0.000122	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	2.01e-05	0.000122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—urinary bladder cancer	2e-05	0.000121	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—urinary bladder cancer	1.99e-05	0.000121	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.99e-05	0.00012	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—urinary bladder cancer	1.98e-05	0.00012	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-05	0.000119	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.96e-05	0.000119	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—urinary bladder cancer	1.93e-05	0.000117	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.89e-05	0.000115	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—urinary bladder cancer	1.89e-05	0.000115	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.89e-05	0.000115	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.89e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—urinary bladder cancer	1.87e-05	0.000113	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—urinary bladder cancer	1.85e-05	0.000113	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—urinary bladder cancer	1.85e-05	0.000112	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—urinary bladder cancer	1.84e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR3—urinary bladder cancer	1.83e-05	0.000111	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.83e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—urinary bladder cancer	1.83e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—urinary bladder cancer	1.82e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ESR1—urinary bladder cancer	1.78e-05	0.000108	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—urinary bladder cancer	1.74e-05	0.000106	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NQO1—urinary bladder cancer	1.74e-05	0.000105	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—urinary bladder cancer	1.73e-05	0.000105	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—urinary bladder cancer	1.72e-05	0.000105	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—urinary bladder cancer	1.72e-05	0.000104	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.72e-05	0.000104	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.69e-05	0.000102	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.68e-05	0.000102	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	0.000101	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—urinary bladder cancer	1.65e-05	9.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—urinary bladder cancer	1.64e-05	9.97e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—urinary bladder cancer	1.61e-05	9.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.61e-05	9.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—urinary bladder cancer	1.6e-05	9.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—urinary bladder cancer	1.6e-05	9.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—urinary bladder cancer	1.59e-05	9.65e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.56e-05	9.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREBBP—urinary bladder cancer	1.56e-05	9.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.55e-05	9.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.55e-05	9.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—urinary bladder cancer	1.54e-05	9.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—urinary bladder cancer	1.54e-05	9.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.53e-05	9.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.52e-05	9.24e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—urinary bladder cancer	1.52e-05	9.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—urinary bladder cancer	1.52e-05	9.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—urinary bladder cancer	1.5e-05	9.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.48e-05	8.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—urinary bladder cancer	1.48e-05	8.95e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.47e-05	8.94e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.47e-05	8.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.46e-05	8.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.45e-05	8.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—urinary bladder cancer	1.45e-05	8.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RHOA—urinary bladder cancer	1.41e-05	8.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.4e-05	8.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—urinary bladder cancer	1.4e-05	8.5e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.37e-05	8.29e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—urinary bladder cancer	1.35e-05	8.2e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMS—urinary bladder cancer	1.35e-05	8.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—urinary bladder cancer	1.33e-05	8.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NCOR1—urinary bladder cancer	1.33e-05	8.08e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—urinary bladder cancer	1.32e-05	8.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—urinary bladder cancer	1.32e-05	8.02e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—urinary bladder cancer	1.31e-05	7.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—urinary bladder cancer	1.29e-05	7.85e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—urinary bladder cancer	1.29e-05	7.85e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX1—urinary bladder cancer	1.28e-05	7.74e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	7.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.26e-05	7.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ERCC2—urinary bladder cancer	1.25e-05	7.6e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—urinary bladder cancer	1.24e-05	7.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—urinary bladder cancer	1.24e-05	7.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—urinary bladder cancer	1.22e-05	7.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	7.32e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—urinary bladder cancer	1.18e-05	7.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.18e-05	7.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	7.14e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	7.08e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	7.08e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.16e-05	7.06e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.16e-05	7.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—urinary bladder cancer	1.15e-05	7e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	6.85e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—urinary bladder cancer	1.13e-05	6.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—urinary bladder cancer	1.12e-05	6.8e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.12e-05	6.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.12e-05	6.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—urinary bladder cancer	1.11e-05	6.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.11e-05	6.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—urinary bladder cancer	1.1e-05	6.69e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	6.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.06e-05	6.46e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—urinary bladder cancer	1.06e-05	6.45e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—urinary bladder cancer	1.05e-05	6.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.05e-05	6.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—urinary bladder cancer	1.04e-05	6.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—urinary bladder cancer	1.03e-05	6.27e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	6.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—urinary bladder cancer	1e-05	6.09e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—urinary bladder cancer	9.55e-06	5.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.38e-06	5.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—urinary bladder cancer	9.26e-06	5.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CREBBP—urinary bladder cancer	9.17e-06	5.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—urinary bladder cancer	9.06e-06	5.5e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	8.72e-06	5.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—urinary bladder cancer	8.56e-06	5.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.36e-06	5.07e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.03e-06	4.87e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.82e-06	4.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—urinary bladder cancer	7.61e-06	4.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—urinary bladder cancer	7.6e-06	4.61e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—urinary bladder cancer	7.51e-06	4.56e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.27e-06	4.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—urinary bladder cancer	7.27e-06	4.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—urinary bladder cancer	7.25e-06	4.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.19e-06	4.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.19e-06	4.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.89e-06	4.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.76e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.58e-06	3.99e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—urinary bladder cancer	6.55e-06	3.97e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.35e-06	3.85e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—urinary bladder cancer	6.25e-06	3.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.74e-06	3.48e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—urinary bladder cancer	5.47e-06	3.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.15e-06	3.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.95e-06	3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.05e-06	2.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.54e-06	2.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.37e-06	2.05e-05	CbGpPWpGaD
